This Is MS Multiple Sclerosis Community: Knowledge & Support

New and improved multiple sclerosis (MS) drugs satisfying key unmet needs of oral administration and increased efficacy suggest a paradigm shift in MS therapy; ending the decade long dominance of interferon betas and Copaxone (glatiramer acetate, Teva) says independent analyst Datamonitor.

The Russian approval of Merck Serono's Movectro (oral cladribine) is a landmark in the treatment for relapsing-remitting MS (RRMS) patients, as it becomes the world's first oral disease-modifying MS therapy to be granted marketing authorization beating Novartis's Gilenia(fingolimod).

Without Tysabri and Extavia launching, Movectro will become the first new MS therapy to enter the $200m Russian MS market in over a decade and this bodes well for European approval expected in the third quarter of 2010...................Read More - http://www.msrc.co.uk/index.cfm/fuseact ... pageid/683

_________________
The Multiple Sclerosis Resource Centre

Squiffy's House of Fun - Laughter for Multiple Sclerosis